Display Settings:

Format

Send to:

Choose Destination
    Nucleic Acids Res. 2005 Jan 14;33(1):439-47. Print 2005.

    Locked nucleic acid (LNA) mediated improvements in siRNA stability and functionality.

    Source

    Center for Genomics and Bioinformatics, Karolinska Institutet 171 77 Stockholm, Sweden. joacim.elmen@cgb.ki.se

    Abstract

    Therapeutic application of the recently discovered small interfering RNA (siRNA) gene silencing phenomenon will be dependent on improvements in molecule bio-stability, specificity and delivery. To address these issues, we have systematically modified siRNA with the synthetic RNA-like high affinity nucleotide analogue, Locked Nucleic Acid (LNA). Here, we show that incorporation of LNA substantially enhances serum half-life of siRNA's, which is a key requirement for therapeutic use. Moreover, we provide evidence that LNA is compatible with the intracellular siRNA machinery and can be used to reduce undesired, sequence-related off-target effects. LNA-modified siRNAs targeting the emerging disease SARS, show improved efficiency over unmodified siRNA on certain RNA motifs. The results from this study emphasize LNA's promise in converting siRNA from a functional genomics technology to a therapeutic platform.

    PMID:
    15653644
    [PubMed - indexed for MEDLINE]
    PMCID:
    PMC546170
    Free PMC Article

    Images from this publication.See all images (5) Free text

    Figure 2
    Figure 4
    Figure 1
    Figure 3
    Figure 5

      Supplemental Content

      Icon for HighWire Press Icon for PubMed Central

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk